Biotherapies for GEP-NETs

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 6, 2012, Pages 833-841

  Öberg, Kjell ^a,b,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c European Neuroendocrine Tumor Society   (Germany)

Author keywords

Combination therapy; GI NET; Interferon; Somatostatin analogue

Indexed keywords

ADENYLATE CYCLASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOPEPTIN; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ABDOMINAL DISCOMFORT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL THERAPY; BLOATING; CANCER REGRESSION; CHOLELITHIASIS; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; RECEPTOR BINDING; STEATORRHEA; TREATMENT RESPONSE;

EID: 84876104293     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.01.001     Document Type: Review

References (55)

1. J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, and J.E. Mares One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 18 2008 3063 3072
2. G.A. Kaltsas, G.M. Besser, and A.B. Grossman The diagnosis and medical management of advanced neuroendocrine tumors Endocr Rev 25 3 2004 458 511
3. G. Rindi, R. Arnold, F.T. Bosman, F. Carneiro, R.H. Hruban, and N.D. Theise Nomenclature and classification of neuroendocrine neoplasms of the digestive system F.T. Bosman, R.H. Hruban, N.D. Theise, WHO classification of tumours of the digestive system 2010 IARC Lyon 13 14
4. G. Kloppel, A. Couvelard, A. Perren, P. Komminoth, A.M. McNicol, and O. Nilsson ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification Neuroendocrinology 90 2 2009 162 166
5. L.J. Hofland, and S.W. Lamberts Somatostatin receptor subtype expression in human tumors Ann Oncol 12 Suppl 2 2001 S31 S36
6. E.T. Janson, and K. Oberg Neuroendocrine tumors-somatostatin receptor expression and somatostatin analog treatment Cancer Chemother Biol Response Modif 21 2003 535 546
7. J.C. Reubi, B. Waser, J.C. Schaer, and J.A. Laissue Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur J Nucl Med 28 7 2001 836 846
8. J.C. Reubi, A. Kappeler, B. Waser, A. Schonbrunn, and J. Laissue Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets J Clin Endocrinol Metab 83 10 1998 3746 3749
9. Y.C. Patel Somatostatin and its receptor family Front Neuroendocrinol 20 3 1999 157 198
10. I. Shimon, J.E. Taylor, J.Z. Dong, R.A. Bitonte, S. Kim, and B. Morgan Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation J Clin Invest 99 4 1997 789 798
11. A. Saveanu, G. Gunz, H. Dufour, P. Caron, F. Fina, and L. Ouafik Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J Clin Endocrinol Metab 86 1 2001 140 145
12. G. Weckbecker, I. Lewis, R. Albert, H.A. Schmid, D. Hoyer, and C. Bruns Opportunities in somatostatin research: biological, chemical and therapeutic aspects Nat Rev Drug Discov 2 12 2003 999 1017
13. K. Oberg Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors Expert Rev Anticancer Ther 9 5 2009 557 566
14. P. Brazeau, W. Vale, R. Burgus, N. Ling, M. Butcher, and J. Rivier Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone Science 179 68 1973 77 79
15. W. Bauer, U. Briner, W. Doepfner, R. Haller, R. Huguenin, and P. Marbach SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 11 1982 1133 1140
16. J. Pless The history of somatostatin analogs J Endocrinol Invest 28 11 Suppl International 2005 1 4
17. P. Caron, I. Morange-Ramos, M. Cogne, and P. Jaquet Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide J Clin Endocrinol Metab 82 1 1997 18 22
18. R.Z. Cai, B. Szoke, R. Lu, D. Fu, T.W. Redding, and A.V. Schally Synthesis and biological activity of highly potent octapeptide analogs of somatostatin Proc Natl Acad Sci U S A 83 6 1986 1896 1900
19. C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, and G. Weckbecker SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 5 2002 707 716
20. R. Arnold, M.E. Trautmann, W. Creutzfeldt, R. Benning, M. Benning, and C. Neuhaus Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours Gut 38 3 1996 430 438
21. B. Eriksson, and K. Oberg Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook Ann Oncol 10 Suppl 2 1999 S31 S38
22. P. Tomassetti, M. Migliori, R. Corinaldesi, and L. Gullo Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR Aliment Pharmacol Ther 14 5 2000 557 560
23. P.N. Maton The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors Gastroenterol Clin North Am 18 4 1989 897 922
24. F. Panzuto, M. Di Fonzo, E. Iannicelli, R. Sciuto, C.L. Maini, and G. Capurso Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma Ann Oncol 17 3 2006 461 466
25. T.M. O'Dorisio, H.S. Mekhjian, and T.S. Gaginella Medical therapy of VIPomas Endocrinol Metab Clin North Am 18 2 1989 545 556
26. J. Rubin, J. Ajani, W. Schirmer, A.P. Venook, R. Bukowski, and R. Pommier Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J Clin Oncol 17 2 1999 600 606
27. S.V. Welin, E.T. Janson, A. Sundin, M. Stridsberg, E. Lavenius, and D. Granberg High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours Eur J Endocrinol 151 1 2004 107 112
28. S. Faiss, U. Rath, U. Mansmann, D. Caird, N. Clemens, and E.O. Riecken Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors Digestion 60 5 1999 469 476
29. D. Granberg, H. Jacobsson, K. Oberg, J. Gustavsson, and M. Lehtihet Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report Digestion 77 2 2008 92 95
30. A. Rinke, H.H. Muller, C. Schade-Brittinger, K.J. Klose, P. Barth, and M. Wied Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 28 2009 4656 4663
31. K. Oberg Endocrine tumors of the gastrointestinal tract: systemic treatment Anticancer Drugs 5 5 1994 503 519
32. D. Grander, K. Oberg, M.L. Lundqvist, E.T. Janson, B. Eriksson, and S. Einhorn Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours Lancet 336 8711 1990 337 340
33. K. Oberg, and B. Eriksson The role of interferons in the management of carcinoid tumours Br J Haematol 79 Suppl 1 1991 74 77
34. K. Oberg The action of interferon alpha on human carcinoid tumours Semin Cancer Biol 3 1 1992 35 41
35. K.M. Detjen, M. Welzel, K. Farwig, F.H. Brembeck, A. Kaiser, and E.O. Riecken Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells Gastroenterology 118 4 2000 735 748
36. P.M. Anderson, E. Katsanis, A.S. Leonard, D. Schow, C.M. Loeffler, and M.B. Goldstein Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases Cancer Res 50 6 1990 1853 1856
37. L.Y. Dirix, P.B. Vermeulen, H. Fierens, B. De Schepper, B. Corthouts, and A.T. Van Oosterom Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors-an antiangiogenic effect? Anticancer Drugs 7 2 1996 175 181
38. B. Biesma, P.H. Willemse, N.H. Mulder, R.C. Verschueren, I.P. Kema, and H.W. de Bruijn Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers Br J Cancer 66 5 1992 850 855
39. M.B. Jacobsen, L.E. Hanssen, F. Kolmannskog, E. Schrumpf, M.H. Vatn, and A. Bergan Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study Scand J Gastroenterol 30 8 1995 789 796
40. K. Oberg Chemotherapy and biotherapy in the treatment of neuroendocrine tumours Ann Oncol 12 Suppl 2 2001 S111 S114
41. T. Shah, and M. Caplin Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours Best Pract Res Clin Gastroenterol 19 4 2005 617 636
42. B. Eriksson, K. Oberg, G. Alm, A. Karlsson, G. Lundqvist, and T. Andersson Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon Lancet 2 8519 1986 1307 1309
43. C.G. Moertel, J. Rubin, and L.K. Kvols Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon J Clin Oncol 7 7 1989 865 868
44. W. Creutzfeldt, H.H. Bartsch, U. Jacubaschke, and F. Stockmann Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide Acta Oncol 30 4 1991 529 535
45. K. Oberg Neuroendocrine gastrointestinal tumours Ann Oncol 7 5 1996 453 463
46. C.H. Veenhof, R. de Wit, B.G. Taal, L.Y. Dirix, J. Wagstaff, and A. Hensen A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour Eur J Cancer 28 1 1992 75 78
47. M.E. Pavel, U. Baum, E.G. Hahn, D. Schuppan, and T. Lohmann Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas J Interferon Cytokine Res 26 1 2006 8 13
48. L.E. Ronnblom, G.V. Alm, and K. Oberg Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment Acta Oncol 30 4 1991 537 540
49. E.M. Tiensuu Janson, H. Ahlstrom, T. Andersson, and K.E. Oberg Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours Eur J Cancer 28A 10 1992 1647 1650
50. M. Frank, K.J. Klose, M. Wied, N. Ishaque, C. Schade-Brittinger, and R. Arnold Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors Am J Gastroenterol 94 5 1999 1381 1387
51. M.L. Fjallskog, A. Sundin, J.E. Westlin, K. Oberg, E.T. Janson, and B. Eriksson Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs Med Oncol 19 1 2002 35 42
52. H. Joensuu, K. Katka, and H. Kujari Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide Acta Endocrinol (Copenh) 126 2 1992 184 185
53. L. Kolby, G. Persson, S. Franzen, and B. Ahren Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 6 2003 687 693
54. S. Faiss, U.F. Pape, M. Bohmig, Y. Dorffel, U. Mansmann, and W. Golder Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 14 2003 2689 2696
55. R. Arnold, A. Rinke, K.J. Klose, H.H. Muller, M. Wied, and K. Zamzow Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 8 2005 761 771